Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 14/20 | 0.73 |
| ▸ | KDR | P35968 | 14/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 13/20 | 0.73 |
| ▸ | EGFR | P00533 | 6/20 | 0.73 |
| ▸ | AURKA | O14965 | 5/20 | 0.63 |
| ▸ | RET | P07949 | 3/20 | 0.63 |
| ▸ | FLT3 | P36888 | 3/20 | 0.63 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.63 |
| ▸ | STK3 | Q13188 | 3/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.63 |
| ▸ | FLT1 | P17948 | 2/20 | 0.63 |
| ▸ | GAK | O14976 | 2/20 | 0.63 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.63 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.63 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.63 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.63 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.63 |
| ▸ | BMPR2 | Q13873 | 2/20 | 0.63 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.63 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144892 | 0.92 | KDR (0.61) | FGFR1KDRPDGFRBEGFRAURKA | |
| SCHEMBL3801007 | 0.90 | AURKA (0.66) | FGFR1KDRPDGFRBEGFRAURKA | |
| SCHEMBL3801013 | 0.90 | AURKA (0.66) | FGFR1KDRPDGFRBEGFRAURKA | |
| SCHEMBL147260 | 0.89 | FGFR1 (0.76) | FGFR1KDRPDGFRBEGFRAURKA | |
| SCHEMBL144252 | 0.87 | KDR (0.68) | FGFR1KDRPDGFRBEGFRRET | |
| SCHEMBL147370 | 0.87 | KDR (0.60) | FGFR1KDRPDGFRBEGFRAURKA | |
| SCHEMBL150090 | 0.87 | KDR (0.60) | FGFR1KDRPDGFRBEGFRAURKA | |
| SCHEMBL144273 | 0.87 | FGFR1 (0.63) | FGFR1KDRPDGFRBEGFRAURKA | |
| SCHEMBL143006 | 0.86 | FGFR1 (0.59) | FGFR1KDRPDGFRBEGFRAURKA | |
| SCHEMBL145476 | 0.85 | MET (0.67) | FGFR1KDRPDGFRBEGFRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | claimed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002096361-A2 | 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | FGFR1 5/4885KDR 1077/4885PDGFRB 467/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | FGFR1 5/4885KDR 1077/4885PDGFRB 467/4885 |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | FGFR1 637/4885KDR 398/4885PDGFRB 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.